Thus, targeting the CD73/CCL5 axis may prove to be a promising strategy for enhancing immunotherapy efficacy in pancreatic cancer marked by hypoxia-induced immunosuppression. This evidence concerns the gene NT5E and familial pancreatic carcinoma.